Short Interest in Lantheus Holdings Inc (NASDAQ:LNTH) Decreases By 9.6%

Lantheus Holdings Inc (NASDAQ:LNTH) saw a large decrease in short interest in June. As of June 30th, there was short interest totalling 950,900 shares, a decrease of 9.6% from the May 30th total of 1,051,400 shares. Based on an average trading volume of 404,500 shares, the days-to-cover ratio is currently 2.4 days. Currently, 2.6% of the company’s stock are sold short.

A number of research analysts have commented on the company. Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 24th. BidaskClub lowered Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $23.33.

In related news, Director Brian A. Markison sold 5,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $24.07, for a total transaction of $120,350.00. Following the completion of the sale, the director now directly owns 87,467 shares of the company’s stock, valued at approximately $2,105,330.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Sam R. Leno sold 3,950 shares of the firm’s stock in a transaction on Friday, June 7th. The shares were sold at an average price of $25.33, for a total value of $100,053.50. Following the sale, the director now directly owns 49,580 shares of the company’s stock, valued at $1,255,861.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 202,908 shares of company stock valued at $5,254,409. 2.60% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of LNTH. WINTON GROUP Ltd bought a new stake in shares of Lantheus during the second quarter worth approximately $594,000. Anderson Fisher LLC bought a new stake in shares of Lantheus during the first quarter worth approximately $112,000. Lazard Asset Management LLC boosted its holdings in shares of Lantheus by 0.8% during the first quarter. Lazard Asset Management LLC now owns 326,835 shares of the medical equipment provider’s stock worth $8,000,000 after acquiring an additional 2,460 shares during the period. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of Lantheus by 5.6% during the first quarter. Vaughan Nelson Investment Management L.P. now owns 1,587,904 shares of the medical equipment provider’s stock worth $38,872,000 after acquiring an additional 84,529 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Lantheus during the first quarter worth approximately $809,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:LNTH traded up $0.30 during midday trading on Monday, hitting $28.06. The company had a trading volume of 219,100 shares, compared to its average volume of 348,198. Lantheus has a 12 month low of $12.59 and a 12 month high of $29.80. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16. The company has a market cap of $1.08 billion, a PE ratio of 29.85, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The business has a fifty day moving average of $26.58.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.03. The business had revenue of $86.51 million for the quarter, compared to analyst estimates of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. On average, sell-side analysts forecast that Lantheus will post 1.11 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Further Reading: Why is cost of goods sold important?

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.